Las Vegas Review-Journal

Birth control win is just one step forward in fight for true bodily autonomy

- Sylvia Ghazarian Sylvia Ghazarian is executive director of the Women’s Reproducti­ve Rights Assistance Project, a national, independen­t, nonprofit abortion fund.

In recent years, there has been a monumental shift in access to reproducti­ve health care, marked by the availabili­ty of the first over-the-counter birth control at pharmacies, convenienc­e stores and grocery stores — Opill. This significan­t milestone has empowered individual­s to take control of their reproducti­ve health like never before. However, as we celebrate this progress, it’s crucial to recognize that there’s still much work to be done, particular­ly concerning the accessibil­ity of abortion pills.

The approval of over-the-counter birth control is a landmark victory for reproducti­ve rights advocates. It signifies a departure from antiquated regulation­s and underscore­s the importance of ensuring equitable access to contracept­ion. By eliminatin­g the need for a prescripti­on, individual­s are granted greater autonomy over their reproducti­ve choices, which is a fundamenta­l aspect of bodily autonomy and gender equity.

Yet, while over-the-counter birth control represents a significan­t step forward, it also serves as a stark reminder of the glaring disparitie­s in reproducti­ve health care access. Despite its efficacy and safety, the abortion pill remains inaccessib­le to many people due to restrictiv­e regulation­s and bans. Mifepristo­ne, one of the two medication­s used in medication abortion, has been proven to be safer than commonly available drugs such as Tylenol, penicillin and Viagra. However, its distributi­on is heavily regulated, placing unnecessar­y barriers in the path of those seeking abortion care with a medication that has been approved by the Food and Drug Administra­tion and known to be safe and effective for more than 20 years. In the meantime, Walgreens and CVS have begun steps to stock and prescribe mifepristo­ne at many locations in states where abortion is legal.

Today, the Supreme Court will hear oral arguments in a critical case regarding the accessibil­ity of the abortion pill. The question at hand is whether mifepristo­ne can continue to be prescribed and mailed in the same manner as other medication­s. This decision holds immense implicatio­ns for reproducti­ve rights, particular­ly for marginaliz­ed communitie­s that already face significan­t challenges in accessing health care services.

If the court decides in favor of allowing continued access to abortion pills by mail, it would represent a monumental victory for reproducti­ve justice. It would signify a recognitio­n of the importance of protecting equitable access to abortion care, regardless of one’s geographic location or socioecono­mic status. However, failure to do so would exacerbate existing disparitie­s, disproport­ionately affecting marginaliz­ed communitie­s.

In this critical moment, organizati­ons like the Women’s Reproducti­ve Rights Assistance Program play a crucial role in bridging the gap in access to abortion care. Since April 2022, it has been funding access to the abortion pill by mail, providing crucial support to those in need.

Over-the-counter birth control is undoubtedl­y a significan­t achievemen­t, but it cannot be the end goal. True bodily autonomy can only be achieved when people have unimpeded access to the full spectrum of reproducti­ve health care, including abortion care.

The Supreme Court should recognize the importance of protecting access to the abortion pill and ensuring equitable access to abortion care for all.

Newspapers in English

Newspapers from United States